Reinhard von Roemeling

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro, Lorenza Rimassa, Ivan Borbath et al. · The Lancet Oncology · 2012 · 549 citations

Second-line Treatment, Placebo-controlled Phase 2, Oncology +11

Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group

Joachim von Pawel, Reinhard von Roemeling, U. Gatzemeier et al. · Journal of Clinical Oncology · 2000 · 285 citations

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Giorgio V. Scagliotti, Joachim von Pawel, Silvia Novello et al. · Journal of Clinical Oncology · 2015 · 256 citations · Full text

Phase I Trial of Concurrent Tirapazamine, Cisplatin, and Radiotherapy in Patients With Advanced Head and Neck Cancer

Danny Rischin, Lester Peters, Rodney J. Hicks et al. · Journal of Clinical Oncology · 2001 · 202 citations

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

Giorgio V. Scagliotti, Silvia Novello, Joan H. Schiller et al. · Clinical Lung Cancer · 2012 · 126 citations · Full text

Non–small-cell Lung Cancer, Oncology, Medicine +7